Floatz logo

Recombinant Human Hyaluronidase

Follicular Lymphoma

National Cancer Institute (NCI)UNKNOWNPhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

196 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclosporin A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulfanum
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB
Vincristine Sulfate
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

Recombinant Human Hyaluronidase is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →
Richter transformationActive
B
Indicative · Phase 3
62 / 100
View asset →
nodular lymphocyte predominant Hodgkin lymphomaActive
B
Indicative · Phase 2/3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →